The United States Patent and Trademark Office (USPTO) has issued patent US12584153B2 to GIVAUDAN SA. This patent grants exclusive rights for an enzyme-mediated method for the production of Amberketal and Amberketal homologues, including the products themselves and their various applications. The patent was filed on April 14, 2021, and is assigned CPC classifications C12P 17/18 and C12N 9/90.

This patent grant is primarily an intellectual property matter for GIVAUDAN SA. For other entities in the biotechnology and pharmaceutical sectors, particularly those involved in enzyme-mediated synthesis or the production of Amberketal and related compounds, this patent signifies potential restrictions on their own research, development, and commercial activities. Companies should review the patent claims to ensure their processes do not infringe upon GIVAUDAN SA's exclusive rights. No immediate compliance actions are required for entities not directly involved in this specific chemical synthesis.